Publicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (24)

2024

  1. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study

    Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172

2023

  1. Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab

    JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846

  2. Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study

    Cancers, Vol. 15, Núm. 18

  3. Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2665-2678), 10.1007/s12094-023-03203-8)

    Clinical and Translational Oncology

  4. Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors

    International Journal of Cardiology, Vol. 382, pp. 52-59

  5. Expert design thinking workshops to analyze users’ perceived applicability of NUTRI-ONCOCARE algorithm to prevent and treat malnutrition in cancer patients under routine clinical practice conditions in Spain: the ALLIANCE study

    Supportive Care in Cancer, Vol. 31, Núm. 9

  6. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

    Therapeutic Advances in Medical Oncology, Vol. 15

  7. Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors

    International Journal of Molecular Sciences, Vol. 24, Núm. 14

  8. SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2665-2678

2022

  1. Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor

    Frontiers in Oncology, Vol. 12

  2. Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

    BMC Cancer, Vol. 22, Núm. 1

  3. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

    European Journal of Cancer, Vol. 161, pp. 26-37

  4. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. Pembrolizumab plus gemcitabine in the subset of triple-negative advanced breast cancer patients in the geicam/2015-04 (Pangea-breast) study

    Cancers, Vol. 13, Núm. 21

  2. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer

    Human Genetics and Genomics Advances, Vol. 2, Núm. 3

2020

  1. Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia

    Breast, Vol. 54, pp. 160-163

2019

  1. HER2 Expression Discordance between Ductal Carcinoma In situ and Invasive Breast Carcinoma. How to Analyze Oncotype DX

    Journal of Cancer Research Updates, Vol. 8, Núm. 1, pp. 1-5

2016

  1. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study

    European Journal of Cancer, Vol. 58, pp. 122-129

  2. Should we do BRCA tests in all triple-negative breast cancers?

    Cancer and Chemotherapy Reviews, Vol. 11, Núm. 2, pp. 48-54

2015

  1. Quimioterapia para el cáncer de mama avanzado triple negativo

    Revisiones en Cancer, Vol. 29, Núm. 4, pp. 177-186